{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:44:47Z","timestamp":1793270687519,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":929,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.bbadis.2010.09.007","type":"journal-article","created":{"date-parts":[[2010,9,18]],"date-time":"2010-09-18T08:57:21Z","timestamp":1284800241000},"page":"70-76","source":"Crossref","is-referenced-by-count":125,"title":["Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy"],"prefix":"10.1016","volume":"1812","author":[{"given":"Mari\u00eblle J.","family":"van Breemen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia M.","family":"Rombach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Poorthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Breunig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2010.09.007_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0010","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"issue":"Suppl 2","key":"10.1016\/j.bbadis.2010.09.007_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1012447102358","article-title":"Natural history of Fabry disease in affected males and obligate carrier females","volume":"24","author":"MacDermot","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/jhg.2010.5","article-title":"Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information","volume":"55","author":"Saito","year":"2010","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0055","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00446279","article-title":"Characterization of alpha-galactosidase isoenzymes in normal and Fabry human-Chinese Hamster somatic cell hybrids","volume":"36","author":"Hamers","year":"1977","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0070","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajhg.2009.09.016","article-title":"Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease","volume":"85","author":"Tajima","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0075","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-008-0920-z","article-title":"Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease","author":"Rohard","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0085","series-title":"The metabolic and molecular bases of inherited disease","first-page":"2741","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"1996"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0090","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0100","first-page":"595","article-title":"Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease","volume":"163","author":"Mills","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0105","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/rcm.1948","article-title":"Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard","volume":"19","author":"Fauler","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0110","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0115","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl 94","key":"10.1016\/j.bbadis.2010.09.007_bb0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"447","author":"Young","year":"2005","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0135","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0140","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0150","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0160","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0165","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0170","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0175","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0140-6736(09)61838-9","article-title":"Enzyme therapy for Fabry's disease: registered for success?","volume":"374","author":"Knebelmann","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0180","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2010.09.007_bb0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-291X(87)80472-2","article-title":"Globoid cell leukodystrophy is a generalized galactosylsphingosine (psychosine) storage disease","volume":"144","author":"Kobayashi","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0215","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/j.1471-4159.2008.05279.x","article-title":"The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease","volume":"105","author":"Giri","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0220","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1523\/JNEUROSCI.5597-08.2009","article-title":"Psychosine accumulates in membrane microdomains in the brain of Krabbe patients, disrupting the raft architecture","volume":"29","author":"White","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2010.09.007_bb0225","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","author":"Sanchez-Ni\u00f1o","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.bbadis.2010.09.007_bb0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443910002073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443910002073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T05:08:40Z","timestamp":1636520920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443910002073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0925443910002073"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2010.09.007","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}